Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoTrust safety evaluation in HER2-positive breast cancer
IRCT20150303021315N16Phase 4Completed
- Sponsor
- AryoGen Biopharma
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by AryoGen Biopharma. Primary endpoint: AryoTrust safety and adverse effects. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20150303021315N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N16.